



Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/590,690-Conf. #2874
				Filing Date	August 25, 2006
				First Named Inventor	Rosanne D. Dunn
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	29729/38914

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US 4,458,066	07-03-1984	Caruthers et al.	
	A2	US 4,542,225	09-17-1985	Blattler et al.	
	A3	US 5,597,569	01-28-1997	Siegall et al.	
	A4	US 6,075,181	06-13-2000	Kucherlapati et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP 1342779		09-10-2003	Fornix Biosciences NV	
	B2	WO 1987/04462		07-30-1987	Celltech Limited, et al.	
	B3	WO 1989/06976		08-10-1989	Quadrant Bioresources Limited	
	B4	WO 1992/07075		04-30-1992	The Wellcome Foundation Ltd.	
	B5	WO 2003/004056		01-16-2003	FB Rice & Co.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C1	ABE et al., Production and immunodiagnostic applications of antihuman light chain monoclonal antibodies, Am. J. Clin. Pathol., 100:67-74, 1993.		
	C2	ANDERSON et al., Management of multiple myeloma today, Semin. Hematol., 36:3-8, 1999.		
	C3	ARPIN et al., The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene Cμ-Cδ switch, and λ light chain expression, J. Exp. Med., 187:1169-1178, 1998.		
	C4	AVET-LOISEAU et al., Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation, Blood, 99:2185-2191, 2002.		
	C5	BEAUCAGE et al., Deoxynucleoside phosphoramidites - a new class of key intermediates for deoxypolynucleotide synthesis, Tetrahedron Lett., 22:1859-1862, 1981.		
	C6	BENATTI et al., Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from <i>Saponaria officinalis</i> , Eur. J. Biochem., 183:465-470, 1989.		
	C7	BERGSAGEL et al., In multiple myeloma, clonotypic B lymphocytes are detectable among CD19 ⁺ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain, Blood, 85:436-447, 1995.		
	C8	BIRD et al., Single-chain antigen-binding proteins, Science, 242:423-426, 1988.		
	C9	BODEY et al., Genetically engineered monoclonal antibodies for direct antineoplastic treatment and cancer cell specific delivery of chemotherapeutic agents, Curr. Pharm. Des., 6:261-276, 2000.		
	C10	BOUX et al., A tumor-associated antigen specific for human kappa myeloma cells, J. Exp. Med., 148:1769-1774, 1983.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/590,690-Conf. #2874
				Filing Date	August 25, 2006
				First Named Inventor	Rosanne D. Dunn
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	29729/38914

	C11	BRADWELL et al., Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine, Clin. Chem., 47:673-680, 2001.	
	C12	BRINKMANN et al., Independent domain folding of <i>Pseudomonas</i> exotoxin and single-chain immunotoxins: influence of interdomain connections, PNAS USA, 89:3075-3079, 1992.	
	C13	BUCHNER et al., A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies, Anal. Biochem., 205:263-270, 1992.	
	C14	CHOW et al., Isolation and DNA sequence of a gene encoding alpha-trichosanthin, a type I ribosome-inactivating protein, J. Biol. Chem., 265:8670-8674, 1990.	
	C15	CLARKE et al., Myeloid-specific gene expression, J. Leukoc. Biol., 63:153-168, 1998.	
	C16	COLCHER et al., Use of monoclonal antibodies as radiopharmaceuticals for the localization of human carcinoma xenografts in nude mice, Meth. Enzymol., 121:802-816, 1986.	
	C17	CÔRBI et al., CD11c integrin gene promoter activity during myeloid differentiation, Leuk. Lymph., 25:415-425, 1997.	
	C18	DALLA-FAVERA et al., BCL-6 and the molecular pathogenesis of B-cell lymphoma, Cold Spring Harb. Symp. Quant. Biol., 59:117-123, 1994.	
	C19	DAVIES et al., Novel therapeutic targets in multiple myeloma, Eur. J. Haematol., 64:359-367, 2000.	
	C20	DEBINSKI et al., A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and <i>Pseudomonas</i> exotoxin, J. Biol. Chem., 268:14065-14070, 1993.	
	C21	DENARDO et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 lym-1 monoclonal antibody, Antibody Immunoconj. Radiopharm., 1:17-33, 1988.	
	C22	DENARDO et al., Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies, Int. J. Biol. Markers, 2:49-53, 1987.	
	C23	DUNN et al., Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin, Immunotech., 2:229-240, 1996.	
	C24	European Search Report (Supplementary), EP 05706314, European Patent Office, 28 June 2007.	
	C25	FISHER et al., Role of PU.1 in hematopoiesis, Stem Cells, 16:25-37, 1998.	
	C26	FONSECA et al., Genetics and cytogenetics of multiple myeloma: a workshop report, Cancer Res., 64:1546-1558, 2004.	
	C27	HABUKA et al., Amino acid sequence of Mirabilis antiviral protein, total synthesis of its gene and expression in <i>Escherichia coli</i> , J. Biol. Chem., 264:6629-6637, 1989.	
	C28	HALLEK et al., Multiple myeloma: increasing evidence for a multistep transformation process, Blood, 91:3-21, 1998.	
	C29	HAROUSSEAU et al., The role of stem cell transplantation in multiple myeloma, Blood Rev., 16:245-253, 2002.	
	C30	HO et al., Cloning of the cDNA of alpha-momorcharin: a ribosome inactivating protein, Biochim. Biophys. Acta, 1088:311-314, 1991.	
	C31	HUSTON et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> , PNAS USA, 85:5879-5883, 1988.	
	C32	International Search Report, PCT/AU2005/000280, Australian Patent Office, 7 April 2005.	
	C33	ISLAM et al., Complete amino acid sequence of luffin-a, a ribosome-inactivating protein from the seeds of <i>Luffa cylindrica</i> , Agric. Biol. Chem., 54:1343-1345, 1990.	
	C34	KERHL et al., Molecular mechanisms regulating CD19, CD20 and CD22 gene expression, Immunol. Today, 15:432-436, 1994.	
	C35	KOVÁŘ et al., HPMa copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia, J. Control. Release, 92:315-330, 2003.	
	C36	KREITMAN et al., Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with <i>Pseudomonas</i> exotoxin, Bioconj. Chem., 4:581-585, 1993.	
	C37	KUNG et al., The complete amino acid sequence of antiviral protein from the seeds of pokeweed (<i>Phytolacca americana</i>), Agric. Biol. Chem., 54:3301-3318, 1990.	
Examiner Signature			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/590,690-Conf. #2874
				Filing Date	August 25, 2006
				First Named Inventor	Rosanne D. Dunn
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	29729/38914

	C38	KYLE, Multiple myeloma: diagnostic challenges and standard therapy, Semin. Hematol., 38:11-14, 2001.	
	C39	KYLE, Update on the treatment of multiple myeloma, Oncologist, 6:119-124, 2001.	
	C40	LAUDER et al., Surface membrane phenotypic expression and treatment response of malignant lymphomas, J. Pathol., 145:259-268, 1985.	
	C41	NAGATA et al., Apoptosis mediated by the Fas system, Prog. Mol. Subcell. Biol., 16:87-103, 1996.	
	C42	NAKANO et al., ELISAs for free light chains of human immunoglobulins using monoclonal antibodies: comparison of their specificity with available polyclonal antibodies, J. Immunol. Meth., 275:9-17, 2003.	
	C43	PASTAN et al., Immunotoxins, Cell, 47:641-648, 1986.	
	C44	RAMSAY et al., Bone marrow purging using monoclonal antibodies, J. Clin. Immunol., 8:81-88, 1988.	
	C45	RYOO et al., Novel therapies for multiple myeloma, Blood Rev., 16:167-174, 2002.	
	C46	SIEGALL et al., Functional analysis of domains II, Ib, and III of <i>Pseudomonas</i> exotoxin, J. Biol. Chem., 264:14256-14261, 1989.	
	C47	SORIA, Immunotoxins, ligand-toxin conjugates and molecular targeting, Pharmacol. Res., 21:35-46, 1989.	
	C48	SUN et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, Hybridoma, 5:517-520, 1986.	
	C49	THORPE et al., New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability <i>in vivo</i> , Cancer Res., 47:5924-5931, 1987.	
	C50	TILLYER et al., Immunoturbidimetric assay for estimating free light chains of immunoglobulins in urine and serum, J. Clin. Pathol., 44:466-471, 1991.	
	C51	TORDSSON et al., Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma, Cancer Immunol. Immunother., 48:691-702, 2000.	
	C52	VITETTA et al., Redesigning nature's poisons to create anti-tumor reagents, Science, 238:1098-1104, 1987.	
	C53	WALDMANN, Monoclonal antibodies in diagnosis and therapy, Science, 252:1657-1662, 1991.	
	C54	WALKER et al., A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent, Adv. Exp. Med. Biol., 186:833-841, 1985.	
	C55	WALKER et al., A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells, Eur. J. Nucl. Med., 12:461-467, 1986.	
	C56	Written Opinion of the International Searching Authority, PCT/AU2005/000280, Australian Patent Office, 7 April 2005.	
	C57	ZHAN et al., Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells, Blood, 99:1745-1757, 2002.	
	C58	ZHANG et al., Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters, Cur. Topics Micro. Immunol., 211:137-147, 1996.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--